Everything below concerns deamidation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-15. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Some sperm banks enable recipients to choose the sex of their child, through methods of sperm sorting. Although the methods used do not guarantee 100% success, the chances of being able to select the gender of a child are held to be considerably increased. Sex selection is controversial, and is illegal in many countries, including Australia, the United Kingdom, and Canada, except when there is a large possibility of a sex-linked genetic disorder. It is legal in the United States, although use for non-medical reasons is discouraged by the American Society for Reproductive Medicine.
In 2025, Newsom signed a budget that restricted new enrollment of undocumented immigrants in Medi-Cal. Newsom signed the California Senate Bill 41 (2025) but vetoed other measures to regulate pharmacy benefit managers.
Castor oil is still used for labor induction in environments where modern drugs are not available; a review of pharmacologic, mechanical, and "complementary" methods of labor induction published in 2024 by the American Journal of Obstetrics and Gynecology stated that castor oil's physiological effect is poorly understood but "given gastrointestinal symptomatology, a prostaglandin mediation has been suggested but not confirmed." According to Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk (2008), castor oil should not be ingested or used topically by pre-term pregnant women. There is no data on the potential toxicity of castor oil for nursing mothers. There is no high-quality research proving that ingestion of castor oil results in cervical ripening or induction of labor; there is, however, evidence that taking it causes nausea, vomiting, and diarrhea. A systematic review of "three trials, involving 233 women, found there has not been enough research done to show the effects of castor oil on ripening the cervix or inducing labour or compare it to other methods of induction. The review found that all women who took castor oil by mouth felt nauseous. More research is needed into the effects of castor oil to induce labour."
Sources: en.wikipedia.org
Most depleted uranium arises as a by-product of the production of enriched uranium for use as fuel in nuclear reactors and in the manufacture of nuclear weapons. Enrichment processes generate uranium with a higher-than-natural concentration of lower-mass-number uranium isotopes (in particular 235U, which is the uranium isotope supporting the fission chain reaction) with the bulk of the feed ending up as depleted uranium. Natural uranium metal contains about 0.71% 235U, 99.28% 238U, and about 0.0054% 234U. The production of enriched uranium using isotope separation creates depleted uranium containing only 0.2% to 0.4% 235U. Because natural uranium begins with such a low percentage of 235U, enrichment produces large quantities of depleted uranium. For example, producing 1 kilogram (2.2 lb) of 5% enriched uranium requires 11.8 kilograms (26 lb) of natural uranium, and leaves about 10.8 kilograms (24 lb) of depleted uranium having only 0.3% 235U. Depleted uranium is further produced by recycling spent nuclear fuel, in which case it contains traces of neptunium and plutonium. These quantities are so small that they are not considered to be of serious radiological significance by the European Committee on Radiation Risk. DU from nuclear reprocessing has different isotopic ratios from enrichment-by-product DU, from which it can be distinguished by the presence of 236U. The only known natural source of uranium with a 235U content significantly different from 0.71% is found in the natural nuclear fission reactor at Oklo, Gabon.
=== Common === Empagliflozin increases the risk of genital fungal infections. The risk is highest in people with a prior history of genital fungal infections. Empagliflozin has been thought to be associated with increased risk of urinary tract infections. Reviews of clinical trials have shown there is no significant risk of developing urinary tract infections while taking empagliflozin when compared to placebo or other diabetic medications. Empagliflozin reduces systolic and diastolic blood pressure and can increase the risk of low blood pressure, which can cause fainting and/or falls. The risk is higher in older people, people taking diuretics, and people with reduced kidney function. Slight increases in Low-density lipoprotein (LDL) cholesterol can be seen with empagliflozin, in the range of 2–4% from baseline. Empagliflozin may cause a temporary decline in kidney function and, in rare cases, acute kidney injury, so it should be used cautiously in patients with kidney impairment. Some evidence suggests it may be safely used in people with significantly reduced kidney function (eGFR ≥ 20 mL/min/1.73 m2) while still providing renal benefits. However, given that this conclusion is largely based on a single major trial, further research is recommended to establish long-term safety and efficacy in this population.
Bolivian officials also asserted that more than 1,660 antidrug operations during 1988 had resulted in the destruction of from 1,000 to 1,400 clandestine cocaine factories and laboratories (80 percent of them in Cochabamba and Santa Cruz departments), the confiscation of about 10,000 kilograms of cocaine, and the arrest of some 700 individuals. The minister of planning and coordination stated in December that 2,900 hectares of coca crops had been eradicated under the financial compensation program. Bolivia's anti-narcotics units apprehended several prominent traffickers in 1988. At the same time that the 1988 Antinarcotics Law was promulgated, the Umopar arrested Suárez at his hacienda in Beni Department. According to one theory, Suárez allowed himself to be arrested in a bid to avoid extradition to the United States. In October 1988, the Special Antinarcotics Forces captured an alleged drug "godfather," Mario Araoz Morales ("El Chichin"), by chance during a training exercise in a jungle area. In November antidrug police in the Chapare also arrested Rosa Flores de Cabrera, alias Rosa Romero de Humérez ("La Chola Rosa"), described as one of the most-wanted women in the Bolivian drugtrafficking network, with connections to the Medellín Cartel. In 1991, under pressure from the United States, Bolivia involved its military forces in anti-drugs actions, despite local opposition. Under the government of Jaime Paz Zamora (1989-1993), antidrug institutions were restructured, but Conalid remained the regulatory body.
The College of Medicine was established by Daniel Drake in 1819 as the Medical College of Ohio, which was the first college of medicine established in the state of Ohio. It became a part of the University of Cincinnati in 1896 and is considered by some historians to be the oldest medical school west of the Allegheny Mountains. It is supposedly the second-oldest public college of medicine in the United States. Other accomplishments include the development of the heart-lung machine, the Fogarty heart catheter, Benadryl, and the Clark oxygen electrode. The college also established the nation's first residency program in emergency medicine. The college is noted for its neurosurgical research into degenerative diseases including Alzheimer's disease and Parkinson's disease. Ranked in the top one-third of American medical schools, the college attracts students from across the United States. In 2008, it became the first medical college in the country to implement the multiple mini interview system pioneered in Canada to better predict candidates with exceptional interpersonal skills, professionalism and ethical judgment. Other medical schools have since adopted the process. In addition to the usual application pathways, the University of Cincinnati offers a dual-admissions program known as Connections to high school students applying for undergraduate studies at the university where students are guaranteed admission to the school if they acquire the required grade point average and MCAT scores. The college attracts many undergraduate students to its summer research fellowships.
Sources: en.wikipedia.org
=== Pharmacodynamics === Methylestradiol is an estrogen, or an agonist of the estrogen receptor. It shows somewhat lower affinity for the estrogen receptor than estradiol or ethinylestradiol. Methylestradiol is an active metabolite of the androgens/anabolic steroids methyltestosterone (17α-methyltestosterone), metandienone (17α-methyl-δ1-testosterone), and normethandrone (17α-methyl-19-nortestosterone), and is responsible for their estrogenic side effects, such as gynecomastia and fluid retention.
== Humphreys' influence == Humphreys influenced generations of sociologists and other social and behavioral scientists in complex ways. He is often studied in research methods classes for the ethical questions that his works raised. However, Earl Babbie, who writes about sociological research methods, notes that the controversy about "sociological snoopers" and research ethics was likely the result of societal homophobia and disgust with the research topic, and not due to real problems with research methods. Schacht credits Humphreys with pioneering research on impersonal sex, now a common topic of research and advocacy in the context of HIV/AIDS. Tewksbury writes about the multiple studies that were inspired by Humphrey's work, calling his work a rich legacy for future sex researchers. According to Brekhus, Humphrey's contribution to sociological theory, in particular to the development of the concept of identity politics, is often overlooked, but should be hailed as an important forerunner to modern queer theory. Nardi also lauds Humphreys' theoretical work, especially his concept of the breastplate of righteousness. Humphreys developed this idea to explain the apparent contradiction of presumably straight, married men holding a public conservative stance against homosexuality, yet engaging in impersonal sex with men in public settings. In 2003, the presidential session at the Society for the Study of Social Problems (SSSP) was devoted to honoring Humphrey's pioneering work on sexuality.
1. Leading theorists wedded to the standard interpretations that allow them to dominate their field, tend first to deny that the anomaly exists; at most, it is a 'blip', an unimportant or transient factor. Initially, structural Realists sought to deny that unipolarity was enduring or important, and predicted its quick demise. Waltz, Mearsheimer, and Layne all predicted in the early 1990s that other powers would soon emerge to balance the US.2. As the salience of the anomaly becomes undeniable, theoreticians redefine or shift their theoretical expectations, so as to contend that the anomaly can indeed be explained by their original theory even if their earlier writings ruled it out. More recently, many structural Realists have acknowledged the existence of unipolarity, or at least have acknowledged the absence of traditional balancing against the US, but have altered standard definitions of balancing behavior in order to reconcile this with balance-of-power theory. Thus, Mearsheimer suggested that Iran and North Korea are balancing, even though the "balance" is not in sight.3. Finally, a band of younger scholars, less invested professionally in the old theory, develops a new interpretation that not only explains the anomaly but places it at its theoretical center. This new theoretical interpretation supersedes the old one and becomes the new 'paradigm' for successive inquiry. In this manner, Robert Pape, T. V.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.